Increased expression of ADAM33 and ADAM8 with disease progression in asthma
SC Foley, AK Mogas, R Olivenstein, PO Fiset… - … of allergy and clinical …, 2007 - Elsevier
BACKGROUND: ADAM33, a disintegrin and metalloproteinase 33 gene, has been identified
as a risk factor for asthma and bronchial hyperresponsiveness and has been postulated as …
as a risk factor for asthma and bronchial hyperresponsiveness and has been postulated as …
[HTML][HTML] Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration
…, LJM Perus, D Moldoveanu, Y Wei, B Fiset… - Nature Cancer, 2021 - nature.com
Metastasis is the leading cause of cancer-related deaths, and obesity is associated with
increased breast cancer (BC) metastasis. Preclinical studies have shown that obese adipose …
increased breast cancer (BC) metastasis. Preclinical studies have shown that obese adipose …
Obesity alters monocyte developmental trajectories to enhance metastasis
…, M De Meo, KD Lach, MSM Issac, B Fiset… - Journal of Experimental …, 2023 - rupress.org
Obesity is characterized by chronic systemic inflammation and enhances cancer metastasis
and mortality. Obesity promotes breast cancer metastasis to lung in a neutrophil-dependent …
and mortality. Obesity promotes breast cancer metastasis to lung in a neutrophil-dependent …
[HTML][HTML] “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
…, CC Cheung, JH Chung, C Couture, PO Fiset… - Modern Pathology, 2020 - Elsevier
Different clones, protocol conditions, instruments, and scoring/readout methods may pose
challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy …
challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy …
Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy
…, K Mann, M Basik, A Bouchard, PO Fiset… - Molecular Cancer …, 2009 - AACR
Nrf2 is the key transcription factor for cytoprotective gene programs. Nrf2 is normally maintained
at very low concentrations by proteasomal degradation, through its interaction with the …
at very low concentrations by proteasomal degradation, through its interaction with the …
[HTML][HTML] … testing for patient selection in immuno-oncology: guidelines for clinical laboratories from the Canadian Association of Pathologists-Association Canadienne …
…, H El-Zimaity, G Fischer, PO Fiset… - Applied …, 2019 - journals.lww.com
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)
checkpoint inhibitors have been approved by various regulatory agencies for the …
checkpoint inhibitors have been approved by various regulatory agencies for the …
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis
Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer (…
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer (…
The innate immune architecture of lung tumors and its implication in disease progression
Lung malignancies are the leading cause of cancer‐related mortality. By virtue of its unique
physiological function, the lung microenvironment is highly dynamic and constantly …
physiological function, the lung microenvironment is highly dynamic and constantly …
[HTML][HTML] The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation
Acute cellular rejection (ACR) is a significant risk factor for chronic lung allograft dysfunction
(CLAD). Although clinically manifest and higher grade (≥A2) ACR is generally treated with …
(CLAD). Although clinically manifest and higher grade (≥A2) ACR is generally treated with …
[HTML][HTML] Canadian multicenter project on standardization of programmed death-ligand 1 immunohistochemistry 22C3 laboratory-developed tests for pembrolizumab …
…, JC Cutz, P Dhamanaskar, PO Fiset… - Journal of Thoracic …, 2020 - Elsevier
Introduction The programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assay is
used to select patients for first or second-line pembrolizumab monotherapy in NSCLC. The …
used to select patients for first or second-line pembrolizumab monotherapy in NSCLC. The …
